Therapeutic impact of cholecalciferol in patients with psychiatric disorders receiving olanzapine

Abstract

Introduction: Psychiatric disorders such as schizophrenia require appropriate treatment. Second-generation antipsychotics, including olanzapine, are administered as an appropriated treatment for these disorders. However, this drug has several complications, such as obesity and increased waist circumference which reduces the acceptance of the treatment. Objectives: The aim of this study was to investigate the effects of vitamin D3 therapy on waist circumference caused by olanzapine. Patients and Methods: In this randomized clinical trial, 50 hospitalized women with psychiatric disorders receiving olanzapine were divided into two groups of intervention and control groups. Before the intervention, the waist circumference, hip circumference, and waist-hip ratio were measured. Then, for 12 weeks, the intervention group received vitamin D3 and the control group received paraffin as the placebo, one pearl every 2 weeks. Waist circumference, hip circumference, and waist-hip ratio were re-measured and the collected data were analyzed by pair t test. Results: Our findings showed that there is a significant decrease in waist circumference and waist-hip ratio in intervention group (P < 0.001). However, these changes were not significant in the placebo group. Hip circumference was not changed significantly in both groups. Conclusion: Vitamin D can be administered concomitant with 0lanzapine to improve side effects of olanzapine such as increasing waist circumference.

Vitamin D supplementation is effective for olanzapine-induced dyslipidemia

“…The present study found that vitamin D supplementation during the exposure period to olanzapine suppressed the increase in the LDL cholesterol level, decrease in the HDL cholesterol level, increase in BMI, and increase in waist circumference. This is the first study to demonstrate the clinical significance of vitamin D in improving blood lipid profiles, since only one previous trial has shown that vitamin D helps in maintaining waist circumference in olanzapine-treated patients ( Kaviyani et al, 2017 ). Despite already being efficient in discovering the olanzapine-vitamin D interaction at the laboratory test level, the JMDC is still unable to precisely locate the onset time pattern of olanzapine-induced dyslipidemia due to the long data collection intervals.…”

Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis

“…Vitamin D supplementation in healthy overweight and obese women increased vitamin D blood concentrations and led to body fat mass reduction [39]. A study on female schizophrenic patients being treated with olanzapine found that administration of vitamin D was generally effective at reducing obesity [40], whereas, conversely, schizophrenic patients with vitamin D deficiency who were under treatment with clozapine did not undergo changes in their metabolic profile nor psychotic status [41].…”